国际标准期刊号: 2161-0681

临床与实验病理学杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 期刊目录
  • 乌尔里希的期刊目录
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Renal Oncocytoma and Cromophobe Renal Cell Carcinoma: Main Morphological Differences and Proposal of a Simple Histochemical and Immunohistochemical Panel to separate them

Gallegos Ivan, Carrasco Gonzalo, Fernandez Cristina, Castillo Octavio and Valdevenito Raul

Introduction: Renal Oncocytoma (RO) and Chromophobe Renal Cell Carcinoma (ChCCR) are within spectrum of “eosinophilic renal neoplasms” that can share morphological features. In some instances, it can be challenging differentiate both entities based only on the HE. For this reason, complementary ancillary techniques are needed.

Methodology: Sixteen RO cases and 21 ChCCR cases were evaluated for macroscopic and microscopic features, defining their architectural, nuclear and special stains criterion. Hale`s Coloidal Iron (HCI), Citokeratin 7 and CD15 were performed.

Results: Significant (p<.001) morphological differences were the pattern of grown (16/16 RO nested type vs 19/21 ChCCR diffuse type), nuclear morphology (“raisinoid” nuclei: 0/16 RO vs. 19/21 ChRCC) and presence of mitotic figure (0/16 RO vs. 16/21 ChCCR). Special stains showed that HCI was positive in 2/16 cases of RO and 20/21 of ChCCR, CK7 was positive in 1/16 cases of RO and 18/21 of ChCCR and CD15 was positive in 13/16 RO and 4/21 of ChCCR (p<.001).

Conclusion: Main differences beetwen RO and ChCCR are respectively the pattern of grown (nested/diffuse), raisinoid nucleus (-/+), and presence of mitosis (-/+). Besides ancillary techniques show HCH (-/+), CK7 (-/+) and CD15 (+/-). The ancillary panel of stains is very easy to perform and useful to achieve the correct diagnosis.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。